… This study sought to determine the impact of weight and body mass index (BMI) on the
safety and efficacy of direct-acting oral anticoagulants (DOACs) compared with warfarin in …

… evaluating the impact of body weight on safety and efficacy of direct oral anticoagulants (DOACs)
as … The efficacy and safety of DOACs is comparable with that of VKA in different weight …

… oral anticoagulant (DOAC)‐treated patients about safety and efficacy in extremes of body
weight… The aims of this systematic review were to investigate the association of body weight …

… of body weight remains controversial. This study aimed to measure the impact of DOACs
compared to warfarin on safety and efficacy outcomes in extreme body weight patients. This …

… oral anticoagulant (DOAC) concentrations and ranges measured in our cohort and values
expected in unselected body weight … Therefore, the clinical impact and consequences on …

… , the impact of the protocol-specified 50% dose reductions applied to patients with body weight
≤60 … in this population, and assessed the impact of protocol-specified dose reductions on …

… From a total of 135,939 new users of oral anticoagulants (OACs) since January 2014, 7,576
warfarin users and 14,103 direct oral anticoagulant (DOAC) users were included in this study…

… , direct-acting oral anticoagulants (DOACs) have … impact of high BW/BMI on renal clearance
because of the aforementioned factors as well as the debate on the most appropriate weight …

… and Haemostasis recommends avoiding the use of direct oral anticoagulants (DOACs) in
patients with a body mass index (BMI) greater than 40 kg/m 2 or weight greater than 120 kg. …

… As prevalence of both obesity and AF increase, the issue of managing anticoagulation in
patients with AF and elevated body weight has become even more essential to address in …